Concepts (201)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hyperlipoproteinemia Type II | 11 | 2023 | 373 | 2.200 |
Why?
|
| Blood Component Removal | 7 | 2020 | 125 | 1.740 |
Why?
|
| Lipoproteins, LDL | 3 | 2013 | 640 | 0.740 |
Why?
|
| Atherosclerosis | 13 | 2023 | 3445 | 0.690 |
Why?
|
| Carotid Artery Diseases | 7 | 2021 | 882 | 0.610 |
Why?
|
| Human Growth Hormone | 9 | 2013 | 683 | 0.590 |
Why?
|
| Colestipol | 1 | 2014 | 10 | 0.510 |
Why?
|
| Cholesterol, LDL | 10 | 2023 | 2356 | 0.510 |
Why?
|
| Niacin | 1 | 2014 | 116 | 0.470 |
Why?
|
| Anticholesteremic Agents | 3 | 2023 | 979 | 0.460 |
Why?
|
| Physicians, Primary Care | 1 | 2020 | 591 | 0.450 |
Why?
|
| Lipoproteins | 4 | 2015 | 878 | 0.420 |
Why?
|
| Maximum Tolerated Dose | 1 | 2013 | 892 | 0.390 |
Why?
|
| Hyperlipoproteinemia Type I | 2 | 2019 | 7 | 0.340 |
Why?
|
| Carotid Arteries | 8 | 2022 | 952 | 0.330 |
Why?
|
| Tunica Media | 4 | 2011 | 113 | 0.300 |
Why?
|
| HIV Infections | 14 | 2022 | 16718 | 0.290 |
Why?
|
| Oligonucleotides | 2 | 2019 | 572 | 0.260 |
Why?
|
| Tunica Intima | 4 | 2011 | 464 | 0.260 |
Why?
|
| Uganda | 8 | 2022 | 1243 | 0.240 |
Why?
|
| Triglycerides | 6 | 2020 | 2454 | 0.240 |
Why?
|
| Abdominal Fat | 3 | 2013 | 223 | 0.210 |
Why?
|
| Lung Diseases, Obstructive | 1 | 2022 | 316 | 0.190 |
Why?
|
| HIV Seronegativity | 1 | 2021 | 211 | 0.190 |
Why?
|
| Heterozygote | 3 | 2019 | 2804 | 0.180 |
Why?
|
| Obesity, Abdominal | 2 | 2013 | 361 | 0.180 |
Why?
|
| Cardiovascular Diseases | 14 | 2023 | 15165 | 0.170 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 2 | 2018 | 294 | 0.170 |
Why?
|
| Growth Hormone-Releasing Hormone | 2 | 2012 | 213 | 0.170 |
Why?
|
| Anti-HIV Agents | 4 | 2021 | 4256 | 0.170 |
Why?
|
| Homozygote | 2 | 2023 | 1785 | 0.170 |
Why?
|
| Urban Health | 1 | 2021 | 547 | 0.160 |
Why?
|
| Acromegaly | 2 | 2012 | 346 | 0.160 |
Why?
|
| Body Composition | 8 | 2013 | 2401 | 0.160 |
Why?
|
| Apolipoprotein C-III | 1 | 2019 | 202 | 0.160 |
Why?
|
| Decision Support Techniques | 2 | 2018 | 1956 | 0.150 |
Why?
|
| HIV Seropositivity | 1 | 2021 | 971 | 0.140 |
Why?
|
| Plaque, Atherosclerotic | 2 | 2021 | 1519 | 0.140 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2017 | 3255 | 0.130 |
Why?
|
| Fasting | 1 | 2020 | 1593 | 0.120 |
Why?
|
| Foundations | 1 | 2013 | 94 | 0.120 |
Why?
|
| Registries | 6 | 2023 | 8089 | 0.110 |
Why?
|
| Endothelium, Vascular | 2 | 2018 | 4456 | 0.110 |
Why?
|
| Antigens, CD | 3 | 2018 | 4026 | 0.110 |
Why?
|
| Risk Factors | 22 | 2022 | 72290 | 0.100 |
Why?
|
| Middle Aged | 35 | 2022 | 213383 | 0.100 |
Why?
|
| Rural Population | 2 | 2020 | 2210 | 0.100 |
Why?
|
| Anti-Retroviral Agents | 2 | 2016 | 1715 | 0.100 |
Why?
|
| Cell Adhesion Molecules | 1 | 2018 | 1602 | 0.100 |
Why?
|
| Inflammation Mediators | 2 | 2018 | 1889 | 0.100 |
Why?
|
| Thrombocytopenia | 1 | 2019 | 1179 | 0.100 |
Why?
|
| Receptors, Cell Surface | 2 | 2018 | 2866 | 0.100 |
Why?
|
| HIV | 1 | 2018 | 1604 | 0.090 |
Why?
|
| Insulin-Like Growth Factor I | 3 | 2013 | 2015 | 0.090 |
Why?
|
| Phosphocreatine | 1 | 2010 | 269 | 0.090 |
Why?
|
| Coronary Disease | 2 | 2016 | 6077 | 0.090 |
Why?
|
| Humans | 45 | 2023 | 744343 | 0.090 |
Why?
|
| Arteries | 1 | 2014 | 1119 | 0.090 |
Why?
|
| Adult | 31 | 2022 | 214055 | 0.090 |
Why?
|
| Azetidines | 1 | 2010 | 142 | 0.080 |
Why?
|
| Cholesterol, HDL | 4 | 2020 | 1814 | 0.080 |
Why?
|
| Treatment Outcome | 10 | 2020 | 63114 | 0.080 |
Why?
|
| Carotid Artery, Common | 2 | 2006 | 183 | 0.080 |
Why?
|
| Cross-Sectional Studies | 9 | 2022 | 25043 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2011 | 552 | 0.080 |
Why?
|
| Arginine | 2 | 2010 | 944 | 0.080 |
Why?
|
| Receptors, LDL | 1 | 2010 | 475 | 0.080 |
Why?
|
| Fingers | 1 | 2011 | 513 | 0.080 |
Why?
|
| Male | 31 | 2022 | 350118 | 0.070 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 1 | 2008 | 138 | 0.070 |
Why?
|
| Obesity | 5 | 2012 | 12745 | 0.070 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2016 | 1873 | 0.070 |
Why?
|
| Female | 34 | 2022 | 380194 | 0.070 |
Why?
|
| Growth Hormone | 1 | 2008 | 705 | 0.070 |
Why?
|
| Health Status Disparities | 1 | 2017 | 1797 | 0.070 |
Why?
|
| Case-Control Studies | 6 | 2021 | 21746 | 0.060 |
Why?
|
| Radiography | 2 | 2014 | 7023 | 0.060 |
Why?
|
| Metformin | 1 | 2012 | 835 | 0.060 |
Why?
|
| Botswana | 2 | 2018 | 1040 | 0.060 |
Why?
|
| Hormone Replacement Therapy | 1 | 2010 | 745 | 0.060 |
Why?
|
| RNA, Messenger | 1 | 2019 | 13033 | 0.060 |
Why?
|
| Adiponectin | 2 | 2008 | 1100 | 0.060 |
Why?
|
| Double-Blind Method | 6 | 2019 | 12026 | 0.060 |
Why?
|
| Lung | 1 | 2022 | 9856 | 0.060 |
Why?
|
| Risk Assessment | 6 | 2021 | 23338 | 0.060 |
Why?
|
| Protease Inhibitors | 1 | 2006 | 791 | 0.050 |
Why?
|
| Coronary Artery Disease | 2 | 2020 | 6487 | 0.050 |
Why?
|
| Ultrasonography | 5 | 2020 | 5985 | 0.050 |
Why?
|
| Adiposity | 1 | 2012 | 1807 | 0.050 |
Why?
|
| Pre-Eclampsia | 1 | 2011 | 1200 | 0.050 |
Why?
|
| Smoking | 2 | 2022 | 8987 | 0.050 |
Why?
|
| Life Style | 1 | 2012 | 3835 | 0.050 |
Why?
|
| C-Reactive Protein | 5 | 2013 | 3778 | 0.050 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2018 | 1155 | 0.040 |
Why?
|
| Testosterone | 1 | 2010 | 2420 | 0.040 |
Why?
|
| United States | 6 | 2023 | 69872 | 0.040 |
Why?
|
| Hypoglycemic Agents | 1 | 2012 | 2872 | 0.040 |
Why?
|
| Spirometry | 1 | 2022 | 864 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 7913 | 0.040 |
Why?
|
| Longitudinal Studies | 3 | 2021 | 13989 | 0.040 |
Why?
|
| Patient Selection | 1 | 2010 | 4215 | 0.040 |
Why?
|
| Lipids | 4 | 2012 | 3305 | 0.040 |
Why?
|
| Injections, Subcutaneous | 1 | 2019 | 666 | 0.040 |
Why?
|
| Mass Screening | 1 | 2013 | 5255 | 0.040 |
Why?
|
| Aged | 11 | 2022 | 163280 | 0.040 |
Why?
|
| Placebos | 2 | 2012 | 1676 | 0.040 |
Why?
|
| Regression Analysis | 4 | 2013 | 6459 | 0.040 |
Why?
|
| Respiratory Function Tests | 1 | 2022 | 1616 | 0.040 |
Why?
|
| Young Adult | 8 | 2019 | 56430 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2016 | 3508 | 0.040 |
Why?
|
| Pilot Projects | 3 | 2017 | 8324 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 12072 | 0.040 |
Why?
|
| Prevalence | 3 | 2021 | 15226 | 0.040 |
Why?
|
| Down-Regulation | 2 | 2016 | 3002 | 0.040 |
Why?
|
| Forced Expiratory Volume | 1 | 2022 | 1743 | 0.040 |
Why?
|
| Overweight | 1 | 2008 | 2371 | 0.040 |
Why?
|
| Platelet Count | 1 | 2019 | 781 | 0.040 |
Why?
|
| E-Selectin | 1 | 2018 | 579 | 0.030 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2018 | 707 | 0.030 |
Why?
|
| Cohort Studies | 4 | 2022 | 40561 | 0.030 |
Why?
|
| Time Factors | 4 | 2021 | 40075 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2019 | 6365 | 0.030 |
Why?
|
| Cardiovascular System | 2 | 2013 | 832 | 0.030 |
Why?
|
| Biostatistics | 1 | 2016 | 162 | 0.030 |
Why?
|
| Inflammation | 1 | 2014 | 10638 | 0.030 |
Why?
|
| Prospective Studies | 4 | 2021 | 53288 | 0.030 |
Why?
|
| Africa South of the Sahara | 1 | 2017 | 724 | 0.030 |
Why?
|
| Odds Ratio | 2 | 2017 | 9849 | 0.030 |
Why?
|
| Lovastatin | 1 | 1994 | 120 | 0.030 |
Why?
|
| Aging | 1 | 2013 | 8664 | 0.030 |
Why?
|
| Hypercholesterolemia | 1 | 2020 | 1151 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2021 | 15076 | 0.030 |
Why?
|
| Health Records, Personal | 1 | 2013 | 124 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2017 | 1677 | 0.030 |
Why?
|
| American Heart Association | 1 | 2017 | 1056 | 0.030 |
Why?
|
| Cholesterol | 2 | 2006 | 2917 | 0.020 |
Why?
|
| Cellulose | 1 | 2011 | 121 | 0.020 |
Why?
|
| Sex Factors | 2 | 2017 | 10397 | 0.020 |
Why?
|
| Dextran Sulfate | 1 | 2011 | 236 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2016 | 1184 | 0.020 |
Why?
|
| Adrenal Insufficiency | 1 | 2012 | 184 | 0.020 |
Why?
|
| Pulsatile Flow | 1 | 2011 | 332 | 0.020 |
Why?
|
| Hyperemia | 1 | 2011 | 225 | 0.020 |
Why?
|
| Solubility | 1 | 2011 | 1085 | 0.020 |
Why?
|
| Mitochondria, Muscle | 1 | 2010 | 171 | 0.020 |
Why?
|
| Viral Load | 1 | 2018 | 3299 | 0.020 |
Why?
|
| Phenotype | 2 | 2017 | 16365 | 0.020 |
Why?
|
| Manometry | 1 | 2011 | 445 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2018 | 3200 | 0.020 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 12245 | 0.020 |
Why?
|
| Cardiology | 1 | 2019 | 1668 | 0.020 |
Why?
|
| Asymptomatic Diseases | 1 | 2011 | 551 | 0.020 |
Why?
|
| Monocytes | 1 | 2017 | 2596 | 0.020 |
Why?
|
| Intra-Abdominal Fat | 1 | 2012 | 591 | 0.020 |
Why?
|
| Body Mass Index | 3 | 2009 | 12720 | 0.020 |
Why?
|
| Blood Glucose | 2 | 2012 | 6256 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2008 | 357 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2014 | 2016 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2016 | 2266 | 0.020 |
Why?
|
| Boston | 2 | 2011 | 9313 | 0.020 |
Why?
|
| Anthropometry | 1 | 2009 | 1350 | 0.020 |
Why?
|
| Disease Progression | 1 | 2021 | 13284 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2011 | 3846 | 0.010 |
Why?
|
| Adolescent | 4 | 2012 | 85781 | 0.010 |
Why?
|
| Exercise Test | 1 | 2010 | 2074 | 0.010 |
Why?
|
| Coronary Angiography | 1 | 1994 | 4577 | 0.010 |
Why?
|
| Body Size | 1 | 2005 | 461 | 0.010 |
Why?
|
| Healthcare Disparities | 1 | 2017 | 3158 | 0.010 |
Why?
|
| Hormones | 1 | 2006 | 889 | 0.010 |
Why?
|
| Comorbidity | 1 | 2016 | 10388 | 0.010 |
Why?
|
| Internet | 1 | 2013 | 3064 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2016 | 7729 | 0.010 |
Why?
|
| Logistic Models | 1 | 2016 | 13408 | 0.010 |
Why?
|
| Cytokines | 1 | 2015 | 7322 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2020 | 77449 | 0.010 |
Why?
|
| Mitochondria | 1 | 2013 | 3520 | 0.010 |
Why?
|
| Massachusetts | 1 | 2013 | 8663 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2009 | 2585 | 0.010 |
Why?
|
| Absorptiometry, Photon | 1 | 2005 | 1725 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 7279 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2006 | 3870 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2008 | 6622 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2014 | 6234 | 0.010 |
Why?
|
| Risk | 1 | 2010 | 9687 | 0.010 |
Why?
|
| Physicians | 1 | 2016 | 4567 | 0.010 |
Why?
|
| Reference Values | 1 | 2005 | 4982 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 39050 | 0.010 |
Why?
|
| Quality of Life | 2 | 2010 | 12804 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 5751 | 0.010 |
Why?
|
| Electronic Health Records | 1 | 2013 | 4468 | 0.010 |
Why?
|
| Hypertension | 1 | 2016 | 8480 | 0.010 |
Why?
|
| Hemodynamics | 1 | 2006 | 4199 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2010 | 4931 | 0.010 |
Why?
|
| Insulin Resistance | 1 | 2008 | 3864 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 17446 | 0.010 |
Why?
|
| Adipose Tissue | 1 | 2006 | 3279 | 0.010 |
Why?
|
| Insulin | 1 | 2008 | 6580 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 57776 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2008 | 8554 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 20129 | 0.010 |
Why?
|
| Pregnancy | 1 | 2011 | 29144 | 0.010 |
Why?
|
Concepts
(201)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(41)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_